Sushmita Pamidi

Sushmita Pamidi

Auto-generated profile, based on publicly available information

Sushmita Pamidi

Respiratory Epidemiology and Clinical Research Unit, Department of Medicine, McGill University, Montreal, Quebec, Canada

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2015 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
SPSushmita Pamidi
Sushmita Pamidi
KWKristen Wroblewski
Kristen Wroblewski
MSMagdalena Stepien
Magdalena Stepien
KSKhalid Sharif-Sidi
Khalid Sharif-Sidi
JKJennifer Kilkus
Jennifer Kilkus
ETEsra Tasali
Esra Tasali
Rationale: Although obstructive sleep apnea (OSA) is associated with impaired glucose tolerance and diabetes, it remains unclear whether OSA treatment with continuous positive airway pressure (CPAP) has metabolic benefits. Objectives: To determine the effect of 8-hour nightly CPAP treatment on glucose metabolism in individuals with prediabetes and OSA. Methods: In a randomized controlled parallel group study, 39 participants were randomly assigned to receive either 8-hour nightly CPAP (n = 26) or oral placebo (n = 13). Sleep was polysomnographically recorded in the laboratory on each night. CPAP adherence was ensured by continuous supervision. Participants continued their daily routine activities outside the laboratory. Glucose metabolism was assessed at baseline and after 2 weeks of assigned treatment using both the oral and intravenous glucose tolerance tests. The primary outcome was the overall glucose response as quantified by the area under the curve for glucose during 2-hour oral glucose tolerance testing. Secondary outcomes included fasting and 2-hour glucose and insulin, the area under the curves for insulin and insulin secretion, norepinephrine, insulin sensitivity, acute insulin response to glucose, and 24-hour blood pressure. Measurements and Main Results: The overall glucose response was reduced (treatment difference: −1,276.9 [mg/dl] · min [95% confidence interval, −2,392.4 to −161.5]; P = 0.03) and insulin sensitivity was improved (treatment difference: 0.77 [mU/L]−1 · min−1 [95% confidence interval, 0.03–1.52]; P = 0.04) with CPAP as compared with placebo. Additionally, norepinephrine levels and 24-hour blood pressure were reduced with CPAP as compared with placebo. Conclusions: In patients with prediabetes, 8-hour nightly CPAP treatment for 2 weeks improves glucose metabolism compared with placebo. Thus, CPAP treatment may be beneficial for metabolic risk reduction. Clinical trial registered with www.clinicaltrials.gov (NCT 01156116)

15 August 2025 in Circulation Research
Verified
Journal Article
Closed access
ETEsra Tasali
Esra Tasali
SPSushmita Pamidi
Sushmita Pamidi
NCNaima Covassin
Naima Covassin
VSVirend K Somers
Virend K Somers
Obstructive sleep apnea (OSA) is a highly prevalent sleep disorder, characterized by recurrent upper airway obstruction during sleep, resulting in intermittent hypoxia, increased sympathetic activation, and sleep deficiency. Over the past 2 decades, there has been a robust body of evidence to support a strong link between OSA and cardiometabolic diseases. Obesity is an important risk factor for OSA. Observational studies indicate that OSA is a strong risk factor for the development of hypertension and diabetes. Moreover, clinical and experimental studies support a causal role of OSA in hypertension and impairments in glucose metabolism, beyond excess weight. Notably, OSA is particularly underdiagnosed and undertreated in women, which may heighten the cardiometabolic risk. OSA is often overlooked during pregnancy and has been linked to adverse cardiometabolic outcomes in observational studies. In randomized clinical trials, treatment of OSA with continuous positive airway pressure reduces blood pressure in individuals with hypertension, but the beneficial effects of continuous positive airway pressure on glycemic outcomes are less convincing. Inconsistent cardiometabolic response to OSA treatment can be partly explained by failure to consider heterogeneity in OSA and variable continuous positive airway pressure adherence among diverse populations. In this review, we summarize the relationships between OSA and cardiometabolic conditions with a particular focus on obesity, hypertension, and diabetes. We review the current knowledge on the heterogeneity in OSA and discuss potential underlying mechanisms for impairments in blood pressure and glucose metabolism in OSA. We also provide a clinical perspective for OSA management considering current research gaps and emerging approaches for the prevention and treatment of cardiometabolic disease.

1 April 2018 in Chest
Verified
Journal Article
Closed access
SPSushmita Pamidi
Sushmita Pamidi
RKR. John Kimoff
R. John Kimoff

1 January 2021 in Chest
Verified
Journal Article
Closed access
RNRaphieal Newbold
Raphieal Newbold
ABAndrea Benedetti
Andrea Benedetti
RKR. John Kimoff
R. John Kimoff
SMSara Meltzer
Sara Meltzer
NGNatasha Garfield
Natasha Garfield
SPSushmita Pamidi
Sushmita Pamidi

Verified
Closed access
SPSushmita Pamidi
Sushmita Pamidi
SRSusan Redline
Susan Redline
DRDavid M Rapoport
David M Rapoport
IAIndu Ayappa
Indu Ayappa
LPLuciana Palombini
Luciana Palombini
ALAmerican Thoracic Society Ad Hoc Committee on Inspiratory Flow Limitation
American Thoracic Society Ad Hoc Committee on Inspiratory Flow Limitation

6 October 2020 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
SPSushmita Pamidi
Sushmita Pamidi
FCFlorian Chapotot
Florian Chapotot
KWKristen Wroblewski
Kristen Wroblewski
HWHarry Whitmore
Harry Whitmore
TPTamar Polonsky
Tamar Polonsky
ETEsra Tasali
Esra Tasali
Background: It has been widely recognized that obstructive sleep apnea (OSA) is linked to cardiovascular disease. Yet, randomized controlled studies failed to demonstrate a clear cardiovascular benefit from OSA treatment, mainly because of poor adherence to continuous positive airway pressure (CPAP). To date, no prior study has assessed the effect of CPAP treatment on daytime resting heart rate, a strong predictor of adverse cardiovascular outcomes and mortality. Methods and Results: We conducted a randomized controlled study in 39 participants with OSA and prediabetes, who received either in‐laboratory all‐night (ie, optimal) CPAP or an oral placebo for 2 weeks. During daytime, participants continued daily activities outside the laboratory. Resting heart rate was continuously assessed over 19 consecutive days and nights using an ambulatory device consisting of a single‐lead ECG and triaxis accelerometer. Compared with placebo, CPAP reduced daytime resting heart rate (treatment difference, −4.1 beats/min; 95% CI, −6.5 to −1.7 beats/min; P =0.002). The magnitude of reduction in daytime resting heart rate after treatment significantly correlated with the magnitude of decrease in plasma norepinephrine, a marker of sympathetic activity ( r =0.44; P =0.02), and the magnitude of decrease in OSA severity (ie, apnea‐hypopnea index [ r =0.48; P =0.005], oxygen desaturation index [ r =0.50; P =0.003], and microarousal index [ r =0.57; P <0.001]). Conclusions: This proof‐of‐concept randomized controlled study demonstrates, for the first time, that CPAP treatment, when optimally used at night, reduces resting heart rate during the day, and therefore has positive cardiovascular carry over effects. These findings suggest that better identification and treatment of OSA may have important clinical implications for cardiovascular disease prevention. Registration: URL: https:/// www.clini​caltr​ials.gov ; Unique identifier: NCT01156116.